Literature DB >> 27528730

Apatinib in Advanced Gastric Cancer: A Doubtful Step Forward.

Lorenzo Fornaro1, Enrico Vasile1, Alfredo Falcone1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27528730      PMCID： PMC5477932          DOI： 10.1200/JCO.2016.68.6931

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  8 in total

1.  Prognostic factor analysis of third-line chemotherapy in patients with advanced gastric cancer.

Authors:  Hyun Jeong Shim; Ju Young Yun; Jun Eul Hwang; Woo Kyun Bae; Sang Hee Cho; Ik Joo Chung
Journal:  Gastric Cancer       Date:  2011-03-23       Impact factor: 7.370

2.  The survival difference between gastric cancer patients from the UK and Japan remains after weighted propensity score analysis considering all background factors.

Authors:  Takanobu Yamada; Takaki Yoshikawa; Masataka Taguri; Tsutomu Hayashi; Toru Aoyama; Henry M Sue-Ling; Kiran Bonam; Jeremy D Hayden; Heike I Grabsch
Journal:  Gastric Cancer       Date:  2015-03-12       Impact factor: 7.370

3.  Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.

Authors:  Charles S Fuchs; Jiri Tomasek; Cho Jae Yong; Filip Dumitru; Rodolfo Passalacqua; Chanchal Goswami; Howard Safran; Lucas Vieira Dos Santos; Giuseppe Aprile; David R Ferry; Bohuslav Melichar; Mustapha Tehfe; Eldar Topuzov; John Raymond Zalcberg; Ian Chau; William Campbell; Choondal Sivanandan; Joanna Pikiel; Minori Koshiji; Yanzhi Hsu; Astra M Liepa; Ling Gao; Jonathan D Schwartz; Josep Tabernero
Journal:  Lancet       Date:  2013-10-03       Impact factor: 79.321

4.  Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data.

Authors:  Ian Chau; Andy R Norman; David Cunningham; Justin S Waters; Jacqui Oates; Paul J Ross
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

5.  Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.

Authors:  Jin Li; Shukui Qin; Jianming Xu; Jianping Xiong; Changping Wu; Yuxian Bai; Wei Liu; Jiandong Tong; Yunpeng Liu; Ruihua Xu; Zhehai Wang; Qiong Wang; Xuenong Ouyang; Yan Yang; Yi Ba; Jun Liang; Xiaoyan Lin; Deyun Luo; Rongsheng Zheng; Xin Wang; Guoping Sun; Liwei Wang; Leizhen Zheng; Hong Guo; Jingbo Wu; Nong Xu; Jianwei Yang; Honggang Zhang; Ying Cheng; Ningju Wang; Lei Chen; Zhining Fan; Piaoyang Sun; Hao Yu
Journal:  J Clin Oncol       Date:  2016-02-16       Impact factor: 44.544

6.  Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.

Authors:  Hansjochen Wilke; Kei Muro; Eric Van Cutsem; Sang-Cheul Oh; György Bodoky; Yasuhiro Shimada; Shuichi Hironaka; Naotoshi Sugimoto; Oleg Lipatov; Tae-You Kim; David Cunningham; Philippe Rougier; Yoshito Komatsu; Jaffer Ajani; Michael Emig; Roberto Carlesi; David Ferry; Kumari Chandrawansa; Jonathan D Schwartz; Atsushi Ohtsu
Journal:  Lancet Oncol       Date:  2014-09-17       Impact factor: 41.316

7.  Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?

Authors:  V Catalano; F Graziano; D Santini; S D'Emidio; A M Baldelli; D Rossi; B Vincenzi; P Giordani; P Alessandroni; E Testa; G Tonini; G Catalano
Journal:  Br J Cancer       Date:  2008-11-04       Impact factor: 7.640

8.  Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma.

Authors:  S-E Al-Batran; E Van Cutsem; S C Oh; G Bodoky; Y Shimada; S Hironaka; N Sugimoto; O N Lipatov; T-Y Kim; D Cunningham; P Rougier; K Muro; A M Liepa; K Chandrawansa; M Emig; A Ohtsu; H Wilke
Journal:  Ann Oncol       Date:  2016-01-07       Impact factor: 32.976
  8 in total
  15 in total

1.  Regorafenib: lights and shadows of antiangiogenic therapies in gastric cancer.

Authors:  Caterina Vivaldi; Alfredo Falcone; Lorenzo Fornaro
Journal:  Transl Gastroenterol Hepatol       Date:  2017-02-23

2.  Influence and mechanism of lung cavitation development on antiangiogenic therapy: is cavitation the new caveat?

Authors:  Lorenzo Calvetti; Giuseppe Aprile
Journal:  Transl Lung Cancer Res       Date:  2019-08

3.  Influence and mechanism of lung cavitation development on antiangiogenic therapy.

Authors:  Man Jiang; Chuantao Zhang; Dong Liu; Yongjie Wang; Hongmei Wang; Tianjun Li; Helei Hou; Na Zhou; Jingjuan Zhu; Hongying Lv; Chuanyu Zhang; Bingliang Fang; Xiaochun Zhang
Journal:  Transl Lung Cancer Res       Date:  2019-08

4.  Apatinib has anti-tumor effects and induces autophagy in colon cancer cells.

Authors:  Wu Lu; He Ke; Ding Qianshan; Wang Zhen; Xiang Guoan; Yu Honggang
Journal:  Iran J Basic Med Sci       Date:  2017-09       Impact factor: 2.699

5.  Combined aspirin and apatinib treatment suppresses gastric cancer cell proliferation.

Authors:  Wei Zhang; Yongsheng Tan; Heping Ma
Journal:  Oncol Lett       Date:  2017-08-31       Impact factor: 2.967

6.  Apatinib for advanced sarcoma: results from multiple institutions' off-label use in China.

Authors:  Lu Xie; Wei Guo; Ye Wang; Taiqiang Yan; Tao Ji; Jie Xu
Journal:  BMC Cancer       Date:  2018-04-06       Impact factor: 4.430

7.  Efficacy and safety of targeting VEGFR drugs in treatment for advanced or metastatic gastric cancer: a systemic review and meta-analysis.

Authors:  Duanrui Liu; Xiaoli Ma; Dongjie Xiao; Yanfei Jia; Yunshan Wang
Journal:  Oncotarget       Date:  2017-12-19

8.  Apatinib Promotes Apoptosis of Pancreatic Cancer Cells through Downregulation of Hypoxia-Inducible Factor-1α and Increased Levels of Reactive Oxygen Species.

Authors:  Ke He; Lu Wu; Qianshan Ding; Farhan Haider; Honggang Yu; Haihe Wang; Guoan Xiang
Journal:  Oxid Med Cell Longev       Date:  2019-02-04       Impact factor: 6.543

9.  Reply to S. Zhang, L. Fornaro et al, and H.J. Lee et al.

Authors:  Shukui Qin; Jin Li
Journal:  J Clin Oncol       Date:  2016-11-01       Impact factor: 44.544

10.  Efficacy and safety of apatinib in patients with previously treated metastatic colorectal cancer: a real-world retrospective study.

Authors:  Miaomiao Gou; Haiyan Si; Yong Zhang; Niansong Qian; Zhikuan Wang; Weiwei Shi; Guanghai Dai
Journal:  Sci Rep       Date:  2018-03-15       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.